COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ: CLGN) has announced a $3.6 million registered direct offering priced at-the-market, selling 1,200,002 ordinary shares at $3.00 per share. The company will also issue unregistered warrants to purchase up to 1,200,002 ordinary shares at a $3.00 exercise price in a concurrent private placement. The warrants will be exercisable immediately with a 3.5-year term. H.C. Wainwright & Co. is serving as the exclusive placement agent. The proceeds will support general corporate purposes, including collaboration with AbbVie on dermal filler development, working capital, and R&D programs. The offering is expected to close around June 2, 2025.

Positive

• Additional $3.6 million in gross proceeds to strengthen balance sheet
• Ongoing partnership with AbbVie for dermal filler product development
• Warrants priced at-the-market with no discount to current trading price

Negative

• Potential dilution for existing shareholders through share issuance
• Additional potential dilution if warrants are exercised
• Small offering size may indicate limited investor interest

Insights

Financial Analyst

CollPlant secured $3.6M financing through a dilutive offering, providing operational runway but signaling possible capital constraints.

CollPlant has announced a $3.6 million registered direct offering priced at-the-market, selling 1,200,002 ordinary shares at $3.00 per share. The structure includes concurrent warrants for an additional 1,200,002 shares at the same $3.00 exercise price, exercisable immediately with a 3.5-year term. This financing structure suggests urgent capital needs rather than strategic positioning.

The pricing at $3.00 per share with equal warrant coverage indicates potential dilution concerns. If all warrants are exercised, this could bring an additional $3.6 million, doubling the current raise to $7.2 million but also doubling the dilution impact. However, with the warrants priced at-the-money rather than at a premium, there's limited incentive for immediate exercise unless share price appreciation occurs.

CEO Yehiel Tal's statement about "shoring up the balance sheet" suggests defensive positioning rather than growth acceleration. The funds will support ongoing R&D and the partnership with AbbVie on their dermal filler product candidate. The use of H.C. Wainwright as placement agent—a firm that frequently works with smaller biotech companies needing capital—further indicates the company's current financial positioning.

This financing, while providing operational runway, reveals CollPlant may be facing capital constraints. The at-market pricing without premium indicates limited leverage in negotiations, though securing any financing in the current biotech funding environment demonstrates investor confidence in their rhCollagen technology platform and AbbVie partnership, which remains a key value driver.

REHOVOT, Israel, May 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,200,002 of the Company's ordinary shares at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered to purchase up to 1,200,002 of the Company's ordinary shares at an exercise price of $3.00 per share. The warrants will be exercisable immediately following the issuance date and have a term of three and one-half years from the issuance date. The offering is expected to close on or about June 2, 2025, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Yehiel Tal, CollPlant's Chief Executive Officer, commented, "We believe the additional capital will help shore up our balance sheet and provide us with additional flexibility to execute on our business plan. We remain committed to creating long-term value for our shareholders as we advance our mission to be a leader in the regenerative and aesthetic medicine space."

The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be approximately $3.6 million. CollPlant intends to use the net proceeds for general corporate purposes, which may include but are not limited to, supporting the work with its business partner, AbbVie, regarding the dermal filler product candidate, working capital and funding its research and development programs.

The ordinary shares (but not the warrants issued in the private placement or the ordinary shares underlying such warrants) are being offered by CollPlant pursuant to a "shelf" registration statement on Form F-3 (File No. 333-269087) originally filed with the U.S. Securities and Exchange Commission (the "SEC") on December 20, 2022 and declared effective by the SEC on January 10, 2023. The ordinary shares to be issued in the registered direct offering are being offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to, and describing the terms of, the registered direct offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus relating to the registered direct offering, when available, may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

The warrants described above are being issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder and, along with the ordinary shares underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying ordinary shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.

For more information about CollPlant, visit http://www.collplant.com.

Forward-Looking Statements

This press release includes forward-looking statements. Forward-looking statements include, but are not limited to, statements relating to the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering, the intended use of proceeds from the registered direct offering, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all, including uncertainties surrounding the methods of fundraising and the Company's preferences regarding such methods, and including its ability to conclude a non-dilutive financing transaction; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or Company's strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based bioink and medical aesthetics products or product candidates including, but not limited to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel, projected capital expenditures and liquidity, changes in the Company's strategy and development plans and projects, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant are contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

CollPlant:
Eran Rotem
Deputy CEO & CFO
+ 972-73-2325600
Eran@collplant.com 

Investors:
LifeSci Advisors
Dan Ferry
daniel@lifesciadvisors.com 

Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-3-6-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-302469369.html

SOURCE CollPlant

FAQ

What is the size and price of CollPlant's (CLGN) new offering?

CollPlant is offering 1,200,002 ordinary shares at $3.00 per share, raising approximately $3.6 million in gross proceeds

How will CollPlant (CLGN) use the proceeds from the offering?

The proceeds will be used for general corporate purposes, including supporting work with AbbVie on dermal filler development, working capital, and R&D programs

What are the terms of the warrants in CollPlant's (CLGN) private placement?

The warrants allow purchase of up to 1,200,002 ordinary shares at $3.00 per share, are immediately exercisable, and have a 3.5-year term

When is CollPlant's (CLGN) offering expected to close?

The offering is expected to close on or about June 2, 2025, subject to customary closing conditions

Who is the placement agent for CollPlant's (CLGN) offering?

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering